Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neupogen and Art-Assist Device in Chronic Limb Threatening Ischemia
NCT02408991Phase 4Withdrawn
- Sponsor
- University of Chicago
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 4 trial of filgrastim in chronic limb-threatening ischemia (CLTI), sponsored by University of Chicago. Planned start Sep 2014; status: withdrawn.
02
Drugs
filgrastim
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on NCT02408991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408991.